For UK pharmaceutical and life sciences leaders
Your UK approval is in place. Why is adoption still lagging behind forecast?
Global launch models routinely underestimate the UK's distinct access environment. NICE sequencing, clinical network dynamics, and payer relationships each require a local approach, and many medicines have already paid the price.
Two minutes. Solva follows up with specific market access options.
- New medicines remaining on formularies for extended periods without significant prescribing
- Field teams reporting resistance from clinicians despite product approval
- Disconnect between national market access strategies and local implementation challenges
- Lower-than-expected patient numbers accessing new therapies post-launch
- Inefficient resource allocation in commercial teams
- Suboptimal field force effectiveness and engagement
- Loss of potential revenue from delayed or foregone launches
- Increased market access costs due to repeated efforts
- Delayed patient access to innovative treatments
- Suboptimal patient outcomes due to lack of advanced therapies
- Perception of UK as a challenging market for innovation
- Damage to company reputation among healthcare professionals
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
UK launch strategy is genuinely different to global. The role of NICE, clinical networks, and payer relationships all require a UK-specific approach that most global models underestimate.
What is the cost of leaving it unaddressed?
46 medicines experienced a negative launch impact in the UK since January 2024 due to commercial and access barriers (ABPI, 2026)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.